Clinical Trials Logo

Osteoporosis, Postmenopausal clinical trials

View clinical trials related to Osteoporosis, Postmenopausal.

Filter by:

NCT ID: NCT02791516 Completed - Clinical trials for Postmenopausal Osteoporosis

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Start date: January 16, 2017
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.

NCT ID: NCT02753283 Completed - Osteoporosis Clinical Trials

Preventing Osteoporosis Using Denosumab

PROUD
Start date: June 2016
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.

NCT ID: NCT02604836 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Start date: June 2004
Phase: Phase 4
Study type: Interventional

This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.

NCT ID: NCT02598934 Completed - Clinical trials for Post Menopausal Osteoporosis

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Start date: August 2004
Phase: Phase 4
Study type: Interventional

This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.

NCT ID: NCT02598453 Completed - Clinical trials for Postmenopausal Osteoporosis

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy due to gastrointestinal (GI) side effects. The anticipated time on study treatment is 12 months, and the target sample size is 517 individuals.

NCT ID: NCT02598440 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.

NCT ID: NCT02589600 Completed - Clinical trials for Osteoporosis, Postmenopausal

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

ZEST II
Start date: January 2016
Phase: Phase 4
Study type: Interventional

The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.

NCT ID: NCT02499237 Completed - Clinical trials for Postmenopausal Osteoporosis

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

AfterDmab
Start date: July 2015
Phase: Phase 4
Study type: Interventional

In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.

NCT ID: NCT02478879 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.

NCT ID: NCT02472782 Completed - Clinical trials for Osteoporosis, Postmenopausal

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

IASIS
Start date: May 2015
Phase:
Study type: Observational [Patient Registry]

This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment. Secondary end-points include correlation between the parameters affecting the physicians' therapeutic choice and the patients' quality of life as well as the evaluation of the whole osteoporosis treatment approach of orthopedic surgeons in Greece (diagnostic means, use of diagnostic and treatment guidelines, methodology of follow - up).